Regarding the two risk factors in Table 1 and Supplementary Table 3, low-performance status is a common risk factor for poor prognosis of GBM, and the past chemotherapy might dampen immunological competence that supports WT1 peptide-based immunotherapy. Here, WT1 is linked to glioblastoma.